Atlas Trials

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

Clinical trial NCT01966107 · COMPLETED

Trial details

NCT number
NCT01966107
Sponsor
AstraZeneca
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
COPDChronic Obstructive Pulmonary DiseaseModerate to Very Severe COPD
Start date
2013-10-16
Primary completion
2017-09-21
Enrollment
3635

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.